Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

• Status: Completed
• Trial end date: 2019-09-29
• Target enrollment: 0
• Participant gender: All

Summary

Prospective study comparing efficacy and safety of intravitreal aflibercept injection and panretinal photocoagulation to early vitrectomy for patients with diabetic vitreous hemorrhage.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Al Hadi Hospital
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Age above 18 years.

• Any sex.

• Type Ι or ΙΙ DM,

• recent diabetic VH which is causing vision impairment, precluding complete PRP and needing treatment.

• BCVA is less than 20/70 (log MAR BCVA 0.6) and better than 20/1000 (log MAR BCVA 1.7).

Exclusion Criteria:

• Tractional retinal detachment.

• Previous PRP.

• History of anti VEGF therapy within the past two months.

• Neovascular glaucoma

• Subhyaloid hemorrhage.

• Vitreomacular traction.

• Diabetic macular edema .

• Patients with systemic contraindications for anti VEGF or unstable medical conditions as uncontrolled hypertension (persistently above 180/110 mmhg) or recent thromboembolic event within the past six months.